Breaking News Instant updates and real-time market news.

TTWO

Take-Two

$99.96

-3.46 (-3.35%)

17:17
05/13/19
05/13
17:17
05/13/19
17:17

Take-Two says won approval to operate 'NBA 2K' in China

  • 13

    May

  • 16

    May

  • 17

    May

  • 29

    May

  • 06

    Jun

  • 08

    Jun

  • 10

    Jun

  • 10

    Jun

  • 10

    Jun

  • 11

    Jun

  • 12

    Jun

  • 13

    Nov

TTWO Take-Two
$99.96

-3.46 (-3.35%)

04/22/19
PIPR
04/22/19
NO CHANGE
PIPR
March NPD video game sales dropped 17% year-over-year, says Piper Jaffray
March NPD video game sales were down 17% year-over-year, and down 8% for the full March quarter, despite a strong lineup of titles, Piper Jaffray analyst Michael Olson tells investors in a research note. Top titles for all of Q1 included Kingdom Hearts III from Square Enix and Nintendo titles Super Smash Bros. Ultimate and New Super Mario Bros. U Deluxe, adds the analyst. Despite the industry decline, Olson believes the data is most positive for Activision Blizzard (ATVI), with incremental title Sekiro: Shadows Die Twice. The data is less positive for Electronic Arts (EA) and Take-Two, says Olson. However, he points out that the EA data does not include free to play title Apex Legends and Take-Two data does not include GTA Online. The analyst maintains Overweight ratings on Activision, EA and Take-Two.
04/29/19
SPHN
04/29/19
NO CHANGE
Target $120
SPHN
Overweight
Stephens makes Take-Two best idea over EA, boosts target to $120 from $110
Stephens analyst Jeff Cohen raised his price target for Take-Two Interactive (TTWO) to $120 from $110 and changed his best idea from Electronic Arts (EA) to the company. The analyst, who still wants to own EA, points out EA shares have outperformed Take-Two and Activision Blizzard (ATVI) year-to-date by ~25% and ~16%, respectively. Take-Two's underperformance has been driven by disappointment with the early results from Red Dead Online, Cohen tells investors in a research note. However, he believes investor expectations around this game have been "right-sized and now the mode has the potential to surprise to the upside once substantial content is added." Further, fan excitement around upcoming releases, Borderlands 3 and The Outer Worlds, has not been priced into the stock, says Cohen. He recommends buying Take-Two ahead of its earnings report on May 13 and keeps an Overweight rating on the shares.
05/01/19
COWN
05/01/19
UPGRADE
COWN
Outperform
Take-Two upgraded to Outperform from Market Perform at Cowen
05/01/19
BTIG
05/01/19
NO CHANGE
BTIG
Twitch viewership of Apex Legends has fallen dramatically, says BTIG
After reaching 50M users within a month, Twitch viewership for Electronic Arts' (EA) Apex Legends has fallen off dramatically, BTIG analyst Brandon Ross told investors yesterday in a blog post. The analyst, who notes he hasn't received a player number from EA's Respawn studio since early March, believes the Twitch metrics are very relevant about the state of in-game engagement. He thinks Apex Legends' engagement has suffered since Respawn has not provided enough content and has introduced content too slowly. Further, there have also been numerous technical problems, adds Ross. The challenges of Respawn to capitalize on the game's fast start show why free-to-play is unlikely to become a major threat to the traditional triple-A video game model, says the analyst. In addition, Ross' survey work indicates Activision Blizzard's Call of Duty was likely impacted the most by Apex Legends.

TODAY'S FREE FLY STORIES

EL

Estee Lauder

$201.74

22.48 (12.54%)

07:37
08/20/19
08/20
07:37
08/20/19
07:37
Recommendations
Estee Lauder analyst commentary  »

Estee Lauder price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

VVUS

VIVUS

$3.46

-0.02 (-0.57%)

07:36
08/20/19
08/20
07:36
08/20/19
07:36
Hot Stocks
VIVUS says study shows addition of Qsymia to LSG surgery improved weight loss »

VIVUS announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPLK

Splunk

$125.55

0.73 (0.58%)

07:36
08/20/19
08/20
07:36
08/20/19
07:36
Recommendations
Splunk analyst commentary  »

Splunk price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 28

    Aug

  • 15

    Oct

TPIC

TPI Composites

$17.49

-0.2 (-1.13%)

07:35
08/20/19
08/20
07:35
08/20/19
07:35
Upgrade
TPI Composites rating change  »

TPI Composites upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Sep

PVTL

Pivotal Software

$13.85

-0.16 (-1.14%)

07:35
08/20/19
08/20
07:35
08/20/19
07:35
Options
Unusual call flow in option market yesterday »

Notable call activity was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

07:35
08/20/19
08/20
07:35
08/20/19
07:35
General news
Treasury Market Outlook: Treasuries are back in rally mode »

Treasury Market Outlook:…

DOW

Dow Inc.

$45.58

1.09 (2.45%)

07:34
08/20/19
08/20
07:34
08/20/19
07:34
Hot Stocks
Dow Inc. to retrofit Louisiana cracker with FCDh technology to produce propylene »

Dow announced it will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 24

    Oct

LULU

Lululemon

$178.63

0.83 (0.47%)

07:34
08/20/19
08/20
07:34
08/20/19
07:34
Recommendations
Lululemon analyst commentary  »

Lululemon earnings and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

EVER

EverQuote

$22.18

0.88 (4.13%)

07:34
08/20/19
08/20
07:34
08/20/19
07:34
Recommendations
EverQuote analyst commentary  »

EverQuote price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ITRI

Itron

$70.02

0.3 (0.43%)

07:33
08/20/19
08/20
07:33
08/20/19
07:33
Downgrade
Itron rating change  »

Itron downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

BIIB

Biogen

$235.61

4.05 (1.75%)

, NVTA

Invitae

$25.78

0.6 (2.38%)

07:32
08/20/19
08/20
07:32
08/20/19
07:32
Hot Stocks
Biogen, Invitae announce availability of SMA STAT test »

Biogen (BIIB) and Invitae…

BIIB

Biogen

$235.61

4.05 (1.75%)

NVTA

Invitae

$25.78

0.6 (2.38%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

MBRX

Moleculin Biotech

$1.15

0.07 (6.48%)

07:32
08/20/19
08/20
07:32
08/20/19
07:32
Hot Stocks
Moleculin Biotech receives Emory University CTRC approval for WP1066 trial »

Moleculin Biotech…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QCOM

Qualcomm

$74.86

1.6 (2.18%)

07:31
08/20/19
08/20
07:31
08/20/19
07:31
Hot Stocks
Qualcomm, LGE enter new global patent license agreement »

Qualcomm announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

  • 06

    Nov

CRM

Salesforce

$143.66

-0.23 (-0.16%)

07:31
08/20/19
08/20
07:31
08/20/19
07:31
Recommendations
Salesforce analyst commentary  »

Salesforce price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 28

    Aug

  • 28

    Aug

  • 12

    Dec

  • 16

    Dec

HAIN

Hain Celestial

$21.88

0.14 (0.64%)

07:28
08/20/19
08/20
07:28
08/20/19
07:28
Downgrade
Hain Celestial rating change  »

Hain Celestial downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Aug

  • 15

    Sep

VNO

Vornado

$61.34

0.14 (0.23%)

07:26
08/20/19
08/20
07:26
08/20/19
07:26
Downgrade
Vornado rating change  »

Vornado downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

MKC

McCormick

$168.53

-1.585 (-0.93%)

07:25
08/20/19
08/20
07:25
08/20/19
07:25
Downgrade
McCormick rating change  »

McCormick downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LVS

Las Vegas Sands

$54.67

2.28 (4.35%)

07:25
08/20/19
08/20
07:25
08/20/19
07:25
Downgrade
Las Vegas Sands rating change  »

Las Vegas Sands…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HD

Home Depot

$207.98

4.335 (2.13%)

07:25
08/20/19
08/20
07:25
08/20/19
07:25
Recommendations
Home Depot analyst commentary  »

Home Depot Q2 results…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Aug

CSCO

Cisco

$48.50

1.54 (3.28%)

07:25
08/20/19
08/20
07:25
08/20/19
07:25
Recommendations
Cisco analyst commentary  »

Cisco 'sum of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

  • 10

    Oct

  • 13

    Nov

RGNX

Regenxbio

$37.50

0.27 (0.73%)

, ADVM

Adverum Biotechnologies

$12.91

-0.5 (-3.73%)

07:24
08/20/19
08/20
07:24
08/20/19
07:24
Upgrade
Regenxbio, Adverum Biotechnologies rating change  »

Regenxbio upgraded to…

RGNX

Regenxbio

$37.50

0.27 (0.73%)

ADVM

Adverum Biotechnologies

$12.91

-0.5 (-3.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

  • 11

    Sep

SILK

Silk Road Medical

$40.85

0.28 (0.69%)

07:24
08/20/19
08/20
07:24
08/20/19
07:24
Initiation
Silk Road Medical initiated  »

Silk Road Medical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Aug

SRPT

Sarepta

$120.16

-4.81 (-3.85%)

07:24
08/20/19
08/20
07:24
08/20/19
07:24
Recommendations
Sarepta analyst commentary  »

Sarepta price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ENTX

Entera Bio

$2.30

-0.24 (-9.45%)

07:24
08/20/19
08/20
07:24
08/20/19
07:24
Hot Stocks
Entera Bio to report results from Phase 2b study for oral PTH in September »

The company said,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Aug

CPB

Campbell Soup

$43.17

0.53 (1.24%)

07:22
08/20/19
08/20
07:22
08/20/19
07:22
Upgrade
Campbell Soup rating change  »

Campbell Soup upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Aug

  • 01

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.